We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$11.9B
AUM Growth
+$1.4B
(+13%)
Cap. Flow
+$748M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
12.11%
Holding
747
New
202
Increased
220
Reduced
153
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$134M |
| 2 |
STMicroelectronics
STM
|
+$103M |
| 3 |
Meta Platforms (Facebook)
META
|
+$89.9M |
| 4 |
MetLife
MET
|
+$71.9M |
| 5 |
Gilead Sciences
GILD
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TE Connectivity
TEL
|
+$161M |
| 2 |
Eli Lilly
LLY
|
+$153M |
| 3 |
MRSH
Marsh
MRSH
|
+$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$91.8M |
| 5 |
Electronic Arts
EA
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.43% |
| 2 | Technology | 17.4% |
| 3 | Industrials | 8.07% |
| 4 | Energy | 6.4% |
| 5 | Financials | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DFTX
376
Definium Therapeutics
DFTX
$5.97B
| $5.7M | 0.05% |
1,002,544
+1,294
| +0.1% | +$9K |
|
377
Scholar Rock
SRRK
$6.06B
| $5.69M | 0.05% |
709,831
+1,644
| +0.2% | +$14.4K |
|
378
SharkNinja
SN
$26B
| $5.52M | 0.05% |
50,747
-169,696
| -77% | -$14.8M |
|
|
APLS
379
DELISTED
Apellis Pharmaceuticals
APLS
| $5.44M | 0.05% |
188,564
+1,564
| +0.8% | +$57.9K |
|
380
ITT
ITT
$19.9B
| $5.34M | 0.04% |
+35,691
| New | +$4.86M |
|
381
Legend Biotech
LEGN
$3.75B
| $5.33M | 0.04% |
109,395
+9,394
| +9% | +$500K |
|
382
RTX Corp
RTX
$297B
| $5.32M | 0.04% |
+43,890
| New | +$5.01M |
|
383
Iovance Biotherapeutics
IOVA
$2.69B
| $5.28M | 0.04% |
+562,435
| New | +$5.33M |
|
|
INZY
384
DELISTED
Inozyme Pharma
INZY
| $5.25M | 0.04% |
1,003,124
+2,451
| +0.2% | +$12.7K |
|
385
NXP Semiconductors
NXPI
$59.5B
| $5.2M | 0.04% |
+21,670
| New | +$5.43M |
|
386
Enovis
ENOV
$1.61B
| $5.12M | 0.04% |
+119,000
| New | +$5.3M |
|
387
Guidewire Software
GWRE
$13.1B
| $5.09M | 0.04% |
+27,827
| New | +$4.23M |
|
388
Domo
DOMO
$178M
| $5.03M | 0.04% |
669,584
+336,117
| +101% | +$2.57M |
|
389
Sweetgreen
SG
$717M
| $5M | 0.04% |
+141,126
| New | +$4.29M |
|
390
Textron
TXT
$15.1B
| $4.99M | 0.04% |
56,307
-239,384
| -81% | -$21.1M |
|
391
Warner Bros
WBD
$66.3B
| $4.81M | 0.04% |
+583,154
| New | +$4.56M |
|
392
Q32 Bio
QTTB
$494M
| $4.77M | 0.04% |
+106,901
| New | +$3.93M |
|
|
WAY
393
Waystar Holding Corp
WAY
$4.47B
| $4.72M | 0.04% |
169,327
-31,481
| -16% | -$776K |
|
394
CRISPR Therapeutics
CRSP
$5.07B
| $4.7M | 0.04% |
100,000
-26,839
| -21% | -$1.36M |
|
395
Humacyte
HUMA
$192M
| $4.62M | 0.04% |
+848,534
| New | +$5.59M |
|
396
Willis Towers Watson
WTW
$31.3B
| $4.53M | 0.04% |
+15,390
| New | +$4.31M |
|
397
FIVE9
FIVN
$2.25B
| $4.5M | 0.04% |
156,553
+101,718
| +185% | +$3.67M |
|
|
OS
398
DELISTED
OneStream Inc
OS
| $4.49M | 0.04% |
+132,385
| New | +$3.9M |
|
399
EverCommerce
EVCM
$1.88B
| $4.44M | 0.04% |
428,735
+124,698
| +41% | +$1.35M |
|
400
FerroAtlántica
GSM
$779M
| $4.43M | 0.04% |
+955,793
| New | +$4.63M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Woodline Partners held 747 positions worth $11.9B, up 13% from $10.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Woodline Partners deployed $748M of net new capital in Q3 2024, opening 202 new positions and adding to 220 existing holdings. Its largest new stake was ASML: 149,876 shares worth $125M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 42% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Eli Lilly, an estimated $153M trimmed.
- Woodline Partners's largest Q3 2024 buy was ASML: 149,876 shares worth $125M.
- Woodline Partners added most to STMicroelectronics in Q3 2024, an estimated $103M increase.
- Woodline Partners's biggest Q3 2024 reduction was Eli Lilly, cutting an estimated $153M.
- Woodline Partners fully exited TE Connectivity in Q3 2024, selling an estimated $161M.
- Woodline Partners's ten largest holdings make up 12% of its $11.9B portfolio in Q3 2024.
- Woodline Partners opened 202 new positions and closed 161 in Q3 2024.
- Woodline Partners's portfolio value rose 13% quarter-over-quarter to $11.9B.
Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.